Keep in mind that Schwartz already gave an indication of what Q4 earnings would be in the press release from Jan 5th:
2014 Net revenue expected in the middle of the established range of $8-$10 million with year-end and fourth quarter earnings to be announced in March.
Hopefully they come in a bit higher than the middle of the range - and the big tell will be how Abstral sales and the launch of the new drug are proceeding in Q1.
Maybe Novartis selected ARWR because they thought they had the best chance of bringing the RNAi products to market. I would speculate that there were at least one or two higher bids for these assets.
ACAD is one of the few companies on the cowen site where there is no link for the webcast. Curious why they are not broadcasting this.
For some reason it won't let me copy-paste the article from Rochester Democrat and Chronicle (posted about an hour ago). Bottom like is that even Daneman is conceding that production quantities are on the way.
So that would be a forward PE of 10 for a company growing at 20%+
I guess that makes sense to some.
FT - February 18, 2015 6:36 pm
Michael Kors has got a problem. He’s too popular. The ubiquity of his bags, with their trademark gold hardware and dangling charm detail, on commuter trains across the world is starting to haunt him. Sales slowed in the last quarter of 2014, especially in North America, where many products were discounted in the run-up to Christmas. And investors have warned that Kors fatigue may continue to slow growth in 2015: year on year, shares have fallen 22 per cent. Suddenly, the Midas of uptown glamour is looking slightly fallible.
Kors’ solution for AW15 was to up the glamour quotient but moderate the bling, offering 56 looks (his “lucky number”, and his upcoming birthday) that drew on Babe Paley, Carolyn Bessette-Kennedy and the Duchess of Windsor to offer his interpretation of “opulent restraint”. Clothes were cut on the bias to shape the body but not cling, and layered with extravagant fabrics such as damask-cut velvet and mink (really), mohair, silk and cashmere.
The focus was on understatement. “I wanted to think of the mother who hasn’t had time to dress and has to run out and do the school run. She just throws on a dressing gown over her nightgown,” Kors explained of the show’s first look. “Except this dressing gown is an oversized fox fur, her nightdress cashmere and her slippers backless burnished leather”.
The theme of nightwear ran throughout the collection: fluid black pyjamas for evening, embroidered with paisley crystals; a peridot silk dress with trumpet skirt in a Windsor-ish dressing-gown print; a peacock Paisley pyjama shirt. Kors continues to champion an alternative red-carpet look that embraces comfort and subtle sophistication. “I grew up when Lauren Hutton would go to the Oscars wearing shorts,” he exclaimed. “So why not wear pyjamas, or separates in the evening — or on the red carpet.” His take on awards’ dressing? A vast pebble crêpe black opera skirt.
Is it possible that they are taking their time with this because they are working with the FDA behind the scenes to ensure that the filing is bullet-proof? There have been so many PDUFA date postponements over the past year - maybe ACAD and FDA want to make sure this doesn't happen so they can approve the drug as soon as possible?
QCOM can't play this game anymore. They have to play hardball now - otherwise there will be no end to this extortion. They should tell s. Korea to go pound sand and that they will no longer supply their market with the technology. You may lose one or two markets that way - but that will be the end of it.
I wonder why AF didn't compare the Auryxia first month launch numbers to those of Renagel and Velphoro. Oh - now I remember - it's because he's a sycophantic lying sack of ****.